Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies

Hanny Al-Samkari, MD, Aric D Parnes, MD, Katayoon Goodarzi, MD, James I Weitzman, MD, Jean M. Connors, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 389.

https://doi.org/10.1182/blood-2019-123864

Published: 2019

Journal Articles

Efficacy and Thrombotic Adverse Events of Romiplostim Use in Patients with Thrombocytopenia Related to Underlying Malignancies

Valery J Li, MD, Yimei Miao, BS, Cy Wilkins, MD, Gerald A. Soff, MD

Blood (2017) 130 (Supplement 1): 2324.

https://doi.org/10.1182/blood.V130.Suppl_1.2324.2324

Published: 2017

Journal Articles

Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT). Results of a Phase 2 Trial

Gerald A. Soff, MD, Yimei Miao, BS, Sean M. Devlin, PhD, Simon Mantha, MD MPH, Jodi V Mones, MD, Valery J Li, MD, Ghassan K Abou-Alfa, MD MBA, Andrea Cercek, MD, Nancy Kemeny, MD, Rekha Parameswaran, MD

Blood (2017) 130 (Supplement 1): 289.

https://doi.org/10.1182/blood.V130.Suppl_1.289.289

Published: 2017

Journal Articles

Management of Anticoagulation in Patients with Hematologic Malignancy Undergoing Autologous Hematopoietic Cell Transplantation

Ang Li, MD, Chris Davis, Qian Wu, Madeline F Kesten, Ajay K Gopal, MD, David A Garcia, MD

Blood (2016) 128 (22): 1437.

https://doi.org/10.1182/blood.V128.22.1437.1437

Published: 2016

Journal Articles

Cytokine and Chemokine Levels Correlate with Apoptosis Markers in Platelets of Pediatric Patients with Immune Thrombocytopenia

Nadine Goelz, Jeannine Winkler, PhD, Julia J.M. Eekels, PhD, Margaret L. Rand, PhD, Oliver Speer, PhD, Markus Schmugge, MD

Blood (2016) 128 (22): 1371.

https://doi.org/10.1182/blood.V128.22.1371.1371

Published: 2016

Journal Articles

Single-Center Experience with Romiplostim for Management of Chemotherapy-Induced Thrombocytopenia (CIT)

Jennifer Miao, Pharm.D., Houry Leblebjian, PharmD, Bridget Fowler-Scullion, Pharm.D., BCOP, Aric Parnes, MD

Blood (2016) 128 (22): 530.

https://doi.org/10.1182/blood.V128.22.530.530

Published: 2016

Journal Articles

Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT)

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Maria Aquila Santoro, MD, Angelo Pomillo, MD, Maria Luci, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2016) 128 (22): 4926.

https://doi.org/10.1182/blood.V128.22.4926.4926

Published: 2016

Journal Articles

Enoxaparin Dose Reduction for Thrombocytopenia in Patients with Cancer: A Quality Assessment Study

Yimei Miao, BS, Gerald A Soff, MD, Rekha Parameswaran, MD, Jonathan Wills, Simon Mantha, MD MPH

Blood (2015) 126 (23): 429.

https://doi.org/10.1182/blood.V126.23.429.429

Published: 2015

Journal Articles

Conditional Knockout of LRP1 in Murine Megakaryocytes and Its Affects on Platelet Factor 4 Biology in Megakaryocytes

Michele P Lambert, MD, Liqing Xiao, Mortimer Poncz, MD

Blood (2014) 124 (21): 4150.

https://doi.org/10.1182/blood.V124.21.4150.4150

Published: 2014

Journal Articles

Importance of Pharmacokinetic Studies in the Management of Acquired Factor X Deficiency

Ming Yeong Lim, MBBChir, Timothy A. McCarthy, MD, Sheh-Li Chen, Pharm D, Alice D Ma, MD

Blood (2014) 124 (21): 5059.

https://doi.org/10.1182/blood.V124.21.5059.5059

Published: 2014

Journal Articles

2-O, 3-O Desulfated Heparin (ODSH) May Mitigate Chemotherapy-Induced Thrombocytopenia and Neutropenia in Patients Treated with Combination Gemcitabine (G)/Nab-Paclitaxel (A), a Myelosuppressive Chemotherapy Regimen

Darren Sigal, MD, Stephen Marcus, MD, Steven J. Cohen, MD, Peter J. Rosen, MD, Tim Nguyen, MD, Thomas Gribbin, MD, Pedro M. Quintana Diez, MD, Mitesh Borad, MD

Blood (2012) 120 (21): 4723.

https://doi.org/10.1182/blood.V120.21.4723.4723

Published: 2012

Journal Articles

2-O, 3-O-Desulfated Heparin (ODSH) Mitigates Chemotherapy-Induced Thrombocytopenia (CIT) by Blocking the Negative Paracrine Effect of Platelet Factor 4 (PF4) On Megakaryopoiesis

Michele Lambert, MD, Samriddhi S Sharma, Liqing Xiao, PhD, Stephen Marcus, MD, Mortimer Poncz, MD

Blood (2012) 120 (21): 386.

https://doi.org/10.1182/blood.V120.21.386.386

Published: 2012

Journal Articles

Platelet Factor 4 (PF4) Levels Are Inversely Correlated with Steady-State Platelet Counts and with Nadir Counts in Chemotherapy-Induced Thrombocytopenia (CIT),

Michele Lambert, MD, Alisa Reznikov, Liqing Xiao, PhD, Mortimer Poncz, MD

Blood (2011) 118 (21): 3527.

https://doi.org/10.1182/blood.V118.21.3527.3527

Published: 2011

Journal Articles

Romiplostim in a Case Series of Chemotherapy-Induced Thrombocytopenia

Rekha Parameswaran, MD, Gerald A. Soff, MD

Blood (2011) 118 (21): 1170.

https://doi.org/10.1182/blood.V118.21.1170.1170

Published: 2011

Journal Articles

Ex Vivo Expanded Megakaryocyte Progenitors Generated From Human Mobilized Peripheral Blood CD34+ Stem Cells Can Be Cryopreserved and Transplanted Into NSG Mice to Generate Functional Platelets

Holger Karsunky, PhD, Robert J. Tressler, PhD, Joy Chananukul, Scientist

Blood (2011) 118 (21): 482.

https://doi.org/10.1182/blood.V118.21.482.482

Published: 2011

Journal Articles

Platelet Factor 4 Levels Inversely Correlate with Platelet Transfusion Needs In Pediatric Patients Treated for Standard Risk Acute Lymphoblastic Leukemia

Michele Lambert, MD, Alisa Reznikov, Yvonne Nguyen, Lubica Rauova, Mortimer Poncz, MD

Blood (2010) 116 (21): 725.

https://doi.org/10.1182/blood.V116.21.725.725

Published: 2010

Journal Articles

Safety of Defibrotide (DF) In Stem Cell Transplant (SCT) Patients (Pts).

Selim Corbacioglu, MD, Enric Carreras, MD, PhD, Dietger W Niederwieser, MD, Marco Sardella, PharmD, Margaret Hoyle, Robin Hume, M.S., Joseph Massaro, Ph.D., Alison L. Hannah, MD, Massimo Iacobelli, MD, Paul G Richardson, Defibrotide Study Group

Blood (2010) 116 (21): 3482.

https://doi.org/10.1182/blood.V116.21.3482.3482

Published: 2010

Journal Articles

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Fredrick Hagemeister, Luis E. Fayad, MD, Xiao Zhou, MD, PHD, Shana Sherril ORoark, APN, Kandice Ames, RN, Maria Alma Rodriguez, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Marcella M. Johnson, MS, Peter McLaughlin, MD, Carlos E. Bueso-Ramos, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Enrique Romaguera

Blood (2010) 116 (21): 1544.

https://doi.org/10.1182/blood.V116.21.1544.1544

Published: 2010

Journal Articles

Long-Acting Interleukin-11 Shows Improved Activity to Increase Platelet Numbers.

Yuni Jung, PhD, Haesook Ahn, Dong-Sik Kim, DVM, Yu Ri Hwang, Seong-Hyun Ho, DVM, Sujeong Kim, PhD, Jong-Mook Kim, PhD

Blood (2009) 114 (22): 3512.

https://doi.org/10.1182/blood.V114.22.3512.3512

Published: 2009

Journal Articles

Safety of Eltrombopag, an Oral Non-Peptide Platelet Growth Factor, in the Treatment of Thrombocytopenia: Results of Four Randomized, Placebo-Controlled Studies

James B. Bussel, MD, John McHutchison, MD, Drew Provan, MD, A. Jagiello-Gruzfeld, MD, Rezvan Rafi, Sophia Goodison

Blood (2007) 110 (11): 1299.

https://doi.org/10.1182/blood.V110.11.1299.1299

Published: 2007

NARROW

A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies

Efficacy and Thrombotic Adverse Events of Romiplostim Use in Patients with Thrombocytopenia Related to Underlying Malignancies

Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT). Results of a Phase 2 Trial

Management of Anticoagulation in Patients with Hematologic Malignancy Undergoing Autologous Hematopoietic Cell Transplantation

Cytokine and Chemokine Levels Correlate with Apoptosis Markers in Platelets of Pediatric Patients with Immune Thrombocytopenia

Single-Center Experience with Romiplostim for Management of Chemotherapy-Induced Thrombocytopenia (CIT)

Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT)

Enoxaparin Dose Reduction for Thrombocytopenia in Patients with Cancer: A Quality Assessment Study

Conditional Knockout of LRP1 in Murine Megakaryocytes and Its Affects on Platelet Factor 4 Biology in Megakaryocytes

Importance of Pharmacokinetic Studies in the Management of Acquired Factor X Deficiency

2-O, 3-O Desulfated Heparin (ODSH) May Mitigate Chemotherapy-Induced Thrombocytopenia and Neutropenia in Patients Treated with Combination Gemcitabine (G)/Nab-Paclitaxel (A), a Myelosuppressive Chemotherapy Regimen

2-O, 3-O-Desulfated Heparin (ODSH) Mitigates Chemotherapy-Induced Thrombocytopenia (CIT) by Blocking the Negative Paracrine Effect of Platelet Factor 4 (PF4) On Megakaryopoiesis

Platelet Factor 4 (PF4) Levels Are Inversely Correlated with Steady-State Platelet Counts and with Nadir Counts in Chemotherapy-Induced Thrombocytopenia (CIT),

Romiplostim in a Case Series of Chemotherapy-Induced Thrombocytopenia

Ex Vivo Expanded Megakaryocyte Progenitors Generated From Human Mobilized Peripheral Blood CD34+ Stem Cells Can Be Cryopreserved and Transplanted Into NSG Mice to Generate Functional Platelets

Platelet Factor 4 Levels Inversely Correlate with Platelet Transfusion Needs In Pediatric Patients Treated for Standard Risk Acute Lymphoblastic Leukemia

Safety of Defibrotide (DF) In Stem Cell Transplant (SCT) Patients (Pts).

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Long-Acting Interleukin-11 Shows Improved Activity to Increase Platelet Numbers.

Safety of Eltrombopag, an Oral Non-Peptide Platelet Growth Factor, in the Treatment of Thrombocytopenia: Results of Four Randomized, Placebo-Controlled Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only